Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 8/20 | 0.65 |
| ▸ | METAP1 | P53582 | 4/20 | 0.65 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.51 |
| ▸ | ANPEP | P15144 | 3/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.51 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848452 | 1.00 | METAP2 (0.65) | METAP2METAP1ERAP1ANPEPERAP2 | |
| SCHEMBL21458090 | 1.00 | METAP2 (0.65) | METAP2METAP1ERAP1ANPEPERAP2 | |
| SCHEMBL5848773 | 1.00 | METAP2 (0.65) | METAP2METAP1ERAP1ANPEPERAP2 | |
| Hydrochloric Acid SCHEMBL9369961 | 0.98 | METAP2 (0.63) | METAP2METAP1ERAP1ANPEPERAP2 | |
| SCHEMBL28123950 | 0.89 | GRIK1 (0.58) | METAP2METAP1ERAP1ANPEPERAP2 | |
| SCHEMBL5849399 | 0.89 | GRIK1 (0.58) | METAP2METAP1ERAP1ANPEPERAP2 | |
| SCHEMBL28028154 | 0.87 | METAP2 (0.63) | METAP2METAP1ERAP1ANPEPERAP2 | |
| Hydrochloric Acid SCHEMBL3840035 | 0.86 | METAP2 (0.61) | METAP2METAP1ERAP1ANPEPERAP2 | |
| SCHEMBL5287440 | 0.83 | SLC1A3 (0.55) | METAP2METAP1ERAP1ANPEPERAP2 | |
| SCHEMBL3841332 | 0.81 | ALPI (0.62) | ANPEPALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | OSAKA CITY UNIVERSITY (JP) | 2023-12-19 | — | — | US | disclosed |
| EP-3466421-B1 | COMPOSITION FOR THE TREATMENT OF PERIPHERAL NERVE DISORDERS | UNIV OSAKA CITY (JP) | 2022-11-30 | — | — | EP | disclosed |
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | OSAKA CITY UNIVERSITY (JP) | 2019-10-17 | — | — | US | disclosed |
| EP-3466421-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | Osaka City University (JP) | 2019-04-10 | — | — | EP | disclosed |
| EP-2647386-B1 | LISSENCEPHALY THERAPEUTIC AGENT | UNIV OSAKA CITY (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-9539298-B2 | Lissencephaly therapeutic agent | OSAKA CITY UNIVERSITY (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20160250276-A1 | LISSENCEPHALY THERAPEUTIC AGENT | OSAKA CITY UNIVERSITY (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371359-B2 | Lissencephaly therapeutic agent | OSAKA CITY UNIVERSITY (JP) | 2016-06-21 | — | — | US | disclosed |
| CN-103282043-B | Congenital agyria therapeutic agent | OSAKA CITY UNIVERSITY (JP) | 2015-09-30 | — | — | CN | disclosed |
| EP-2647386-A1 | LISSENCEPHALY THERAPEUTIC AGENT | Osaka City University (JP) | 2013-10-09 | — | — | EP | disclosed |
| CN-103282043-A | Lissencephaly therapeutic agent | UNIV OSAKA CITY | 2013-09-04 | — | — | CN | disclosed |
| EP-1692098-B1 | ALPHA-KETOAMIDE DERIVATIVE, AND PRODUCTION METHOD AND USE THEREOF | SENJU PHARMA CO (JP) | 2009-10-28 | — | — | EP | disclosed |
| CN-100463901-C | Alpha-ketoamide derivative, and production method and use thereof | SENJU PHARMA CO (JP) | 2009-02-25 | — | — | CN | disclosed |
| US-7491705-B2 | Alpha-ketoamide derivative, and production method and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20070004643-A1 | Alpha-ketoamide derivative, and production method and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| CN-1890210-A | Alpha-ketoamide derivatives, method for producing same and use thereof | SENJU PHARMA CO (JP) | 2007-01-03 | — | — | CN | disclosed |
| EP-1692098-A1 | ALPHA-KETOAMIDE DERIVATIVE, AND PRODUCTION METHOD AND USE THEREOF | Senju Pharmaceutical Co., Ltd. (JP) | 2006-08-23 | — | — | EP | disclosed |
| US-6960575-B2 | For use as inhibitors of chymase | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-11-01 | — | — | US | disclosed |
| WO-2005056519-A1 | ALPHA-KETOAMIDE DERIVATIVE, AND PRODUCTION METHOD AND USE THEREOF | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2005-06-23 | — | — | WO | disclosed |
| US-6713472-B1 | 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | PMP22, PRPH, NGF | METAP2 4654/4885METAP1 4787/4885ERAP1 4811/4885 |
| US-20070004643-A1 | Alpha-ketoamide derivative, and production method and use thereof | CAPN1, CAPN2, CAPNS1 | METAP2 2437/4885METAP1 1687/4885ERAP1 477/4885 |
| US-20160250276-A1 | LISSENCEPHALY THERAPEUTIC AGENT | ASPH, DCX, P4HA1 | METAP2 2692/4885METAP1 3365/4885ERAP1 3459/4885 |
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | PMP22, PRPH, NGF | METAP2 4654/4885METAP1 4787/4885ERAP1 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.